The three therapies
Prolotherapy: injection of an irritant, usually concentrated dextrose, into ligaments, tendons or joints to trigger a healing inflammatory response. Cheapest, oldest, weakest evidence.
Platelet-rich plasma (PRP): your own blood is spun to concentrate platelets and their growth factors, then injected. Mid-cost, and the best-supported of the three for several specific conditions.
Mesenchymal stem cells (MSCs): cells from your bone marrow or fat (same-day), or culture-expanded cells from your tissue or a donor (multi-day, laboratory processed). Most expensive, most regulated, evidence variable by condition and product.
Evidence by condition
| Condition | Prolotherapy | PRP | MSC injection |
|---|---|---|---|
| Knee osteoarthritis, KL 1-3 | L3: small trials, modest benefit | L2: multiple RCTs favor leukocyte-poor PRP over hyaluronic acid for 6-12 months | L2-L3: RCTs show pain/function gains; structural repair unproven |
| Lateral epicondylitis (tennis elbow) | L3 | L2: consistent benefit vs steroid at 6-12 months | L3-L4: little added over PRP |
| Achilles / patellar tendinopathy | L3 | L2-L3: mixed; better in patellar than Achilles | L3 |
| Rotator cuff, partial tears | L4 | L2-L3: reduced retear after repair; modest for non-surgical | L3 |
| Plantar fasciitis | L3 | L2: durable vs steroid | L4 |
| Chronic low back / SI ligament pain | L3: prolotherapy's best-studied niche | L3 | L3 |
Grades follow our L1 to L4 framework. Where MSC and PRP evidence are similar, PRP is the rational first choice because it costs a fraction and carries no regulatory ambiguity.
Cost in 2026 (typical ranges, not quotes)
| Therapy | Colombia | United States |
|---|---|---|
| Prolotherapy, per session | USD 80-250 | USD 150-500 |
| PRP, per joint or site | USD 200-600 | USD 500-2,000 |
| Same-day BMAC or adipose MSC, per joint | USD 1,800-4,500 | USD 3,000-8,000 |
| Culture-expanded MSC, per joint | USD 3,500-8,000 | Not lawfully marketed; Florida-state clinics USD 6,000-12,000 |
A rational sequence
- Load management, physical therapy, weight, footwear, activity modification. Boring and better-evidenced than any injection.
- PRP for tendon problems and mild-to-moderate knee OA, one to three sessions, with a real rehab program attached.
- Prolotherapy as a low-cost option for ligament laxity and some back pain, or when PRP is unaffordable.
- MSC injection only when PRP has failed or the condition is one where MSCs have specific evidence, with imaging-guided delivery and a clinic that documents its product; see why imaging guidance is non-negotiable.
- Surgery when structural damage or KL 4 disease makes biologics a poor bet.
Skipping rungs is how people spend USD 8,000 on a problem PRP would have handled
A clinic that recommends expanded stem cells as first-line for tennis elbow or a KL 2 knee is optimizing for its revenue, not your outcome. Ask why PRP is not being suggested first and listen carefully to the answer.
See stem cells vs PRP vs cortisone for how steroid injections fit, and steroid washout timing if you have already had cortisone.
Regulatory status: FDA vs INVIMA
United States (FDA): No stem cell product is FDA-approved for orthopedic, neurologic, or systemic use. Minimally manipulated same-day autologous procedures are marketed under a narrow exemption; culture-expanded cells and most umbilical products are unapproved biologics and the FDA's authority over them was reaffirmed in federal court in 2024. Florida's 2025 law permits certain treatments under state rules but does not create FDA approval.
Colombia (INVIMA): Cell therapies are regulated as advanced-therapy products. Clinics require INVIMA habilitation for the facility and, for laboratory-processed products, product-level authorization or an approved research protocol. Ask to see the INVIMA registration number and verify the treating physician on ReTHUS. "INVIMA registered" for the clinic is not the same as an authorized product.
Frequently asked questions
Is PRP better than stem cells?
For tennis elbow, plantar fasciitis and mild knee osteoarthritis, PRP has comparable or better evidence at a fraction of the cost. MSCs have not shown consistent superiority in head-to-head trials.
Does prolotherapy work?
Evidence is L3: some small trials show benefit for knee OA and ligament-related back pain, but quality is low. It is cheap and low-risk, which is its main argument.
Can I combine PRP and stem cells?
Many clinics do. There is little controlled evidence that the combination outperforms either alone; treat it as a cost question.
Not sure which rung you are on?
Send your imaging report and what you have tried. We will tell you whether PRP, MSCs or neither makes sense, and which Colombian clinics do each properly.
WhatsApp Andy in MedellínRequest a quote